Glucosamine and Chondroitin Effects
- Conditions
- Inflammation
- Interventions
- Dietary Supplement: Glucosamine and ChondroitinDietary Supplement: placebo
- Registration Number
- NCT01682694
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Brief Summary
A common starting dose of glucosamine and chondroitin will reduce inflammation as reflected by a reduction in serum C-reactive protein.
- Detailed Description
Use of glucosamine and chondroitin have been associated with reduced cancer and overall mortality. The aim of this study is to determine whether a common starting dose of glucosamine and chondroitin (1500 mg/d + 1200 mg/d, respectively) reduces systemic inflammation as reflected by a reduction in high sensitivity C-reactive protein.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
- Healthy
- Overweight (body mass index kg/m2 (BMI) between 25 and 32.5)
- Non-smoking men and women
- Aged 20-55y
- Chronic medical illness, history of gastrointestinal, hepatic, or renal disorders, or inflammatory conditions (including autoimmune and inflammatory diseases)
- Pregnancy or lactation
- Currently on a weight-loss diet
- BMI (body mass index) < 25 or > 30
- Alcohol intake of greater than 2 drinks/day
- Current use of prescription or over-the-counter medications, (Excluding oral contraceptives and hormone-secreting IUDs), including use of aspirin or NSAIDs more than 2 days per week
- Abnormal renal, liver or metabolic test
- Inability to swallow pills
- Known allergy to shellfish
- Not willing to take pills made from shellfish or animal sources
- Intention to relocate out of study area within next 4 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Glucosamine and Chondroitin Glucosamine and Chondroitin Glucosamine and Chondroitin Placebo placebo Inactive ingredients
- Primary Outcome Measures
Name Time Method hsCRP 1 year hsCRP is a biomarker of systemic inflammation
- Secondary Outcome Measures
Name Time Method untargeted (exploratory) serum metabolomics (differences in small molecule abundance ratios) 1 year The mechanisms of action of glucosamine and chondroitin are currently unknown. Untargeted metabolomic assays of serum will be undertaken for exploratory analyses of potential effects of glucosamine and chondroitin. Significant differences in abundance ratios of small molecules between the intervention and placebo will be reported.
Trial Locations
- Locations (1)
Fred Hutchinson Cancer Research Center
🇺🇸Seattle, Washington, United States